OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Related Articles
New Ancestry-adjusted Lung Cancer Prediction Model
A new ancestry-adjusted risk prediction model, Genomic-informed Care for Motivating High Risk Individuals Eligible for Evidence-based Prevention (GREAT), may aid patients in decision-making around lung…
Tricking cells into trashing cancer
In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist Behnam Nabet and his collaborators describe how…
Victoriaâs Secret Global Fund for Womenâs Cancers Career Development Awards, in Partnership with Pelotonia & AACRÂ
$206,000 over two years for female assistant professors conducting research with a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis, or…
Combos Deemed Safe, Effective in Recurrent Glioblastoma – Oncology Nurse Advisor
Combination treatment with retifanlimab, bevacizumab, and hypofractionated radiotherapy â with or without epacadostat â warrants further investigation, according to researchers.
FDA Issues Guidance Considerations for Tissue Biopsies in Clinical Trials
According to the FDA, biopsies should be optional in clinical protocol when information will be used to evaluate only non-key secondary end points.
Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma
This nonrandomized clinical trial reports outcomes for children with low-risk relapsed Hodgkin lymphoma treated with second-line chemotherapy and involved-field radiotherapy without autologous stem cell transplant.
Mount Sinaiâs Nina Bhardwaj Elected to National Academy of Medicine for Contributions to Cancer Immunotherapy
Nina Bhardwaj, MD, PhD, of Mount Sinai has been elected to the National Academy of Medicine for her pioneering work in cancer immunotherapy.
Trispecific Antibody Therapy Well-Tolerated Among Patients With Relapsed/Refractory Multiple Myeloma
According to a phase 1 dose escalation study among patients with relapsed/refractory multiple myeloma, treatment with novel BCMA-CD38-CD3-targeting trispecific antibody ISB 2001 was well-tolerated.
Actigraphy: Wearable Devices in ALS Research and Care
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Burden of femaleâspecific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021
Unequal age distribution and incidence have been identified in four female-specific cancer burdens, which highlights the need for individualized national cancer control strategies throughout womenâs…
